Psyched Wellness Hires the National Research Council of Canada to Test AME-1
Toronto, Ontario, May 11 2021 – Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has contracted the National Research Council of Canada (NRC), an agency of the Government of Canada. The NRC specializes in providing vital scientific and technological services to the research and industrial communities of Canada. The NRC was hired to provide their expertise in biomedical nanotechnology, but all the results of the research will belong to Psyched, and the NRC does not endorse the findings or Psyched products.
This contract will be divided into 3 objectives over a period of 2 years to further preliminary findings indicating anti-inflammatory and antioxidant properties in addition to the study of potential neuroprotective roles of the AME-1 extract. This study is the first successive one to further explore the neuroprotective, anti-inflammatory, and antioxidant nature of the AME-1 extract from the Amanita Muscaria mushroom concentrating on gut health and neuroprotection. Gut health can be impaired and lead to inflammation thus promoting a chronic condition of the gut lining and impairment of barrier function of the digestive tract. This is significant as gut health and immunity promotion is significant for the health and wellness of an individual. Neuroprotection is the preservation of neuronal structure or the rate of function. Preliminary evidence of a neuroprotective role of AME-1 would be a key initial step in the discovery of a new novel health and wellness property of the Amanita Muscaria mushroom.
“This investigative study will reveal key nutritional systematic and functional properties of the AME-1 extract. The Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach using modern scientific methods to help understand the functional neuroprotective and immune properties of AME-1,” says Brian Tancowny, scientific advisor to Psyched.
“We are very proud to announce this agreement with the NRC, the results of this study will further demonstrate the tremendous potential we believe we have with AME-1 for people’s health and wellness.” says Jeffrey Stevens, CEO of the Company.